Combination Therapy with JAK2 inhibitors in MPN

The continued evolution and refinement of strategies for disease diagnosis, risk assessment, therapeutic intervention and disease management have provided patients with hematologic malignancies and benign hematologic disorders with enhanced outcomes and improved quality of life.
The 2016 Great Debates & Updates in Hematologic Malignancies conference, held April 1-2 in New York, NY, provided clinicians with the most current and pertinent data in the areas of multiple myeloma (MM), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), acute leukemia, myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), lymphoma and benign hematology. This Key Insights™ activity provides a summary of the key ‘take home’ points from the meeting.
In this presentation, Dr. Ruben A. Mesa discusses combination therapy with JAK2 inhibitors in the treatment of myeloproliferative neoplasms (MPN).
A continuing education program is offered as a supplement to this webcast at the following location:
elc.imedex.com/...
© 2016 Imedex, LLC.